A Phase 4 interventional study of Everolimus and Mycophenolate mofetil Tablet/Capsule in Heart Transplant, sponsored by Chong Kun Dang Pharmaceutical. Not yet recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-04-24.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy and safety of lower dose calcineurin inhibitors (CNI) in combination with Everolimus in Korean heart transplant recipients.
This study is a prospective, multicenter, open-label, randomized, comparative, phase 4 trial to optimize immunosuppressive therapy using everolimus and low-dose calcineurin inhibitors in heart transplant patients in Korea.
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Everolimus
Drug: Everolimus
Mycophenolate mofetil
Drug: Mycophenolate mofetil Tablet/Capsule
Up to 1.5g BID(total 3g daily), PO - Check the blood concentration of Everolimus at each visit
Also known as: Certirobell Tablet
Drug page: Mycophenolic Acid
Up to 1.5g BID(total 3g daily), PO
Also known as: Myrept® Cap./Tab.
hierarchical composite assessed using the win-ratio
hierarchical composite assessed using the win-ratio, including graft survival, treated rejection episodes, change in percent atheroma volume, and change in eGFR.
Time frame: baseline, 12 months
Graft rejection
Time to onset of Graft rejection
Time frame: Baseline and 6, 12 months after drug administrations
Newly developed Graft dysfunction
Frequency of incidence
Time frame: Baseline and 6, 12 months after drug administrations
Change in renal function
Change in eGFR
Time frame: Baseline and 6, 12 months after drug administrations
CAV ISHLT grade
Coronary Arterial Vasculopathy(CAV) assessed by ISHLT grade for CAV (ISHLT: International Society for Heart and Lung Transplantation) * CAV0 (Not significant): No detectable angiographic lesion * CAV1 (Mild): Angiographic LM\<50% or Primary vessel with maximum lesion\<70% or Branch stenosis\<70% * CAV2 (Moderate): Angiographic LM\<50%, Single primary vessel≥70% or Isolated branch stenosis in 2 system≥70% * CAV3 (Severe): Angiographic LM≥50% or ≥2 primary vessels ≥70% or Isolated branch stenosis in all 3 system≥70% or CAV1 or CAV2 with allograft dysfunction (LVEF≤45%) or evidence of significant restrictive physiology
Time frame: Until 12 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Dec 2030, 64 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus
Chong Kun Dang Pharmaceutical →